Lymphokines, E.g., Interferons, Interlukins, Etc. Patents (Class 530/351)
-
Patent number: 9034310Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.Type: GrantFiled: February 20, 2003Date of Patent: May 19, 2015Inventor: Stephen B. Cantrell
-
Publication number: 20150132257Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: ApplicationFiled: December 12, 2014Publication date: May 14, 2015Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 9028808Abstract: The present invention relates to a cytokine for use in the treatment and/or control of dependent and/or addictive behavior, in particular addiction and/or dependency to nicotine, food addiction, alcohol addiction and/or sex addiction. The present invention also relates to treatment and/or control of withdrawal and/or symptoms of withdrawal from an addiction, in particular nicotine addiction, food addiction, alcohol addiction and/or sex addiction. The present invention further relates to the induction of loss of interest or aversion to the addictive substance or behavior, such as nicotine, over-indulgence in high-calorie, high-fat foods, and to other behaviors or addictions that are hazardous to the health.Type: GrantFiled: January 27, 2011Date of Patent: May 12, 2015Assignee: Immunservice GmbHInventor: Edith Huland
-
Publication number: 20150125421Abstract: The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.Type: ApplicationFiled: October 31, 2014Publication date: May 7, 2015Inventor: Mark D. Mannie
-
Publication number: 20150126709Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: July 2, 2014Publication date: May 7, 2015Inventors: Oliver HILL, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Publication number: 20150125419Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: June 30, 2014Publication date: May 7, 2015Inventors: Oliver HILL, Christian Gieffers, Meinolf Thiemann
-
Publication number: 20150126710Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: ApplicationFiled: July 2, 2014Publication date: May 7, 2015Inventors: Oliver HILL, Marcus Branschädel, Christian Gieffers, Meinolf Thiemann
-
Patent number: 9023358Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.Type: GrantFiled: March 4, 2014Date of Patent: May 5, 2015Assignee: Eli Lilly and CompanyInventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
-
Patent number: 9023337Abstract: Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.Type: GrantFiled: April 8, 2010Date of Patent: May 5, 2015Assignee: University of Southern CaliforniaInventors: Tingchao Chen, Yi Zhao, W. French Anderson
-
Publication number: 20150118153Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: ApplicationFiled: May 6, 2013Publication date: April 30, 2015Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang
-
Publication number: 20150118185Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.Type: ApplicationFiled: November 7, 2014Publication date: April 30, 2015Inventor: Paul L. DeAngelis
-
Publication number: 20150111279Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: December 19, 2014Publication date: April 23, 2015Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20150110740Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.Type: ApplicationFiled: September 26, 2014Publication date: April 23, 2015Applicant: Massachusetts Institute of TechnologyInventors: Li Tang, Darrell J. Irvine
-
Publication number: 20150110737Abstract: The invention is directed to a method of preparing B-cells that produce interleukin-10 (IL-10), or IL-10 per se, which comprises contacting one or more B-cells ex vivo with an isolated interleukin-35 (IL-35) protein, and culturing the one or more B-cells under conditions to provide one or more B-cells that produce IL-10. The invention also is directed to a method of suppressing the proliferation of lymphocytes in vitro or in vivo by contacting lymphocytes with an isolated IL-35 protein. The invention further is directed to a method of suppressing autoimmunity in a mammal by administering to the mammal an IL-35 protein or IL-10-producing B-cells.Type: ApplicationFiled: April 11, 2013Publication date: April 23, 2015Inventors: Charles Emeka Egwuagu, Ren-Xi Wang, Cheng-rong Yu
-
Publication number: 20150105537Abstract: A codon optimized nucleic acid sequence for Interferon Alpha-2a is provided which can be used for expression of Interferon Alpha-2a in E. Coli.Type: ApplicationFiled: March 28, 2013Publication date: April 16, 2015Applicant: BIOGENOMICS LIMITEDInventors: Archana Rajesh Krishnan, Sanjay Madhukar Sonar, Damodar Krishnabahadur Thappa
-
Patent number: 9005598Abstract: Novel compounds of the general formula (I): in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR via two nucleophilic moieties.Type: GrantFiled: March 4, 2010Date of Patent: April 14, 2015Assignee: Polytherics LimitedInventors: Antony Robert Godwin, Stephen James Brocchini
-
Patent number: 9005600Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: December 18, 2012Date of Patent: April 14, 2015Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 8999670Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.Type: GrantFiled: April 22, 2013Date of Patent: April 7, 2015Assignee: OPKO Biologics Ltd.Inventors: Fuad Fares, Udi Eyal Fima
-
Publication number: 20150093358Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also discarded.Type: ApplicationFiled: November 26, 2014Publication date: April 2, 2015Inventors: FUAD FARES, UDI EYAL FIMA
-
Publication number: 20150094451Abstract: The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an IgG CH1 domain and a second polypeptide having an immunoglobulin constant region where there is at least one mutation in the IgG CH3 domain that abolishes the ability of the second polypeptide to bind CH3-specific affinity media such that the first and second polypeptides have different affinities with respect to CH1 and CH3 specific affinity reagents that allows rapid isolation by differential binding of the first and second polypeptides to these affinity reagents. The invention also provides bispecific antibodies that have IgG CH1 and CH3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding of the IgG regions to these affinity reagents. The invention also concerns bispecific antibodies which are heterodimers of heavy chains, i.e.Type: ApplicationFiled: September 3, 2014Publication date: April 2, 2015Inventors: Nicolas Fischer, Giovanni Magistrelli, Francois Rousseau, Krzysztof Masternak, Pauline Malinge
-
Publication number: 20150093357Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Applicant: UNIVERSITY OF CONNECTICUTInventors: Leo Lefrancois, Thomas A. Stoklasek
-
Publication number: 20150093800Abstract: The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.Type: ApplicationFiled: September 5, 2014Publication date: April 2, 2015Inventors: Ekta MAHAJAN, Kapil KOTHARY, Joanna SO, Jay WERBER
-
Patent number: 8993266Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: GrantFiled: December 20, 2012Date of Patent: March 31, 2015Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason Sagert
-
Patent number: 8993519Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.Type: GrantFiled: October 25, 2012Date of Patent: March 31, 2015Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Jason Benjamin Bock, Xia Luo
-
Patent number: 8993724Abstract: The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.Type: GrantFiled: June 14, 2011Date of Patent: March 31, 2015Assignee: Ares Trading S.A.Inventors: Dina Fischer, Alain Bernard, Paul Ducommun, Mara Rossi
-
Publication number: 20150086506Abstract: Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.Type: ApplicationFiled: May 19, 2014Publication date: March 26, 2015Applicant: University of Louisville Research Foundation, Inc.Inventor: Haval Shirwan
-
Patent number: 8987210Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.Type: GrantFiled: August 8, 2013Date of Patent: March 24, 2015Assignee: Jyant Technologies, Inc.Inventor: James W. Lillard, Jr.
-
Patent number: 8980581Abstract: The invention provides certain embodiments relating to methods and compositions for incorporating non-natural amino acids into a polypeptide or protein by utilizing a mutant or modified aminoacyl-tRNA synthetase to charge the non-natural amino acid to a the corresponding tRNA. In certain embodiments, the tRNA is also modified such that the complex forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with unmodified tRNA/aminoacyl-tRNA synthetase pairs.Type: GrantFiled: August 16, 2013Date of Patent: March 17, 2015Assignee: California Institute of TechnologyInventors: Pin Wang, Inchan Kwon, Soojin Son, Yi Tang, David Tirrell
-
Patent number: 8980245Abstract: The present application discloses new PEG-interferon lambda 1 conjugates (PEG-IFN?1), processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same. These conjugates have increased blood half-lives and persistence time compared to IFN?1 and are effective in the treatment of hepatitis B and hepatitis C.Type: GrantFiled: May 1, 2013Date of Patent: March 17, 2015Assignee: Nanogen Pharmaceutical BiotechnologyInventor: Nhan Ho
-
Patent number: 8980267Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.Type: GrantFiled: March 4, 2013Date of Patent: March 17, 2015Assignee: ImmunGene IncInventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
-
Publication number: 20150072396Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.Type: ApplicationFiled: March 1, 2012Publication date: March 12, 2015Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
-
Publication number: 20150072398Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.Type: ApplicationFiled: August 20, 2014Publication date: March 12, 2015Inventors: Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Bertozzi
-
Publication number: 20150064185Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.Type: ApplicationFiled: November 13, 2014Publication date: March 5, 2015Inventors: Lucy J. HOLT, Ian M. Tomlinson
-
Publication number: 20150056162Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.Type: ApplicationFiled: January 25, 2013Publication date: February 26, 2015Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
-
Patent number: 8962811Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.Type: GrantFiled: April 3, 2013Date of Patent: February 24, 2015Assignee: Ohio UniversityInventors: Marcia J. Kieliszewski, Jianfeng Xu, John Kopchick, Shigeru Okada, Gary Meyer
-
Publication number: 20150050278Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.Type: ApplicationFiled: March 14, 2013Publication date: February 19, 2015Inventors: Dimiter S. Dimitrov, Tianlei Ying
-
Publication number: 20150050715Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc.Type: ApplicationFiled: October 22, 2014Publication date: February 19, 2015Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20150050215Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: September 14, 2012Publication date: February 19, 2015Applicant: Axon Neuroscience SEInventors: Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka
-
Publication number: 20150051441Abstract: The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue.Type: ApplicationFiled: August 12, 2014Publication date: February 19, 2015Inventors: Nadia Gopichandran, Nicolas Michel Orsi, David Andrew Brooke
-
Patent number: 8956605Abstract: The present invention relates to use an agent for the prevention and/or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases.Type: GrantFiled: January 11, 2010Date of Patent: February 17, 2015Assignee: Generon (Shanghai) CorporationInventors: Yu Liang Huang, Zhi Hua Huang, Qi Sun
-
Patent number: 8956623Abstract: The present invention relates to a recombinant fusion interferon for animals, a pharmaceutical composition thereof, and the use of the recombinant fusion interferon. The recombinant fusion interferon is represented by formula (I) or formula (II), (Porcine interferon)-(Linker)n-(Porcine immunoglobulin Fc fragment) ??(I) (Porcine immunoglobulin Fc fragment)-(Linker)n-(Porcine Interferon) ??(II) wherein n is 0 or a positive integer between 1 to 10, the recombinant fusion IFN specifically binds an antibody that specifically binds porcine interferon and an antibody that specifically binds porcine immunoglobulin Fc fragment.Type: GrantFiled: July 17, 2013Date of Patent: February 17, 2015Assignee: SBC Virbac LimitedInventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
-
Publication number: 20150044134Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.Type: ApplicationFiled: January 18, 2013Publication date: February 12, 2015Applicant: UNIVERSITY OF MIAMIInventors: Izidore Lossos, Shruti Bhalt, Joseph Rosenblatt, Seung-Uon Shin
-
Publication number: 20150038678Abstract: This invention relates to interleukin-10 (IL-10) polypeptide conjugates comprising at least one non-naturally-encoded amino acid.Type: ApplicationFiled: February 28, 2013Publication date: February 5, 2015Applicant: Ambrx, Inc.Inventors: Kristin S. Eaton, Melanie Nelson
-
Publication number: 20150038679Abstract: The disclosure provides methods for targeting interleukin-3 receptor-expressing cells, particularly inhibiting the growth of such cells by using an interleukin-3 (IL-3) variant conjugated to a toxin that will affect cells expressing the interleukin-3 receptor. Further disclosed are interleukin-3 (IL-3) variants comprising one or more non-naturally encoded amino acids, and the structures of non-naturally encoded amino acids.Type: ApplicationFiled: February 28, 2013Publication date: February 5, 2015Applicant: Ambrx, Inc.Inventors: Melanie Nelson, Kristin S. Eaton
-
Patent number: 8945528Abstract: This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.Type: GrantFiled: August 30, 2011Date of Patent: February 3, 2015Assignee: Generon (Shanghai) Corporation Ltd.Inventors: Xiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Yuliang Huang
-
Patent number: 8945897Abstract: The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.Type: GrantFiled: December 16, 2011Date of Patent: February 3, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Richard Sheinecker, Hanspeter Rottensteiner, Peter Turecek
-
Patent number: 8945558Abstract: The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed.Type: GrantFiled: October 20, 2006Date of Patent: February 3, 2015Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Miyuki Kobara
-
Patent number: 8946161Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.Type: GrantFiled: October 2, 2013Date of Patent: February 3, 2015Assignee: Ratiopharm GmbHInventors: Walter Hinderer, Heinz Lubenau
-
Patent number: 8945553Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: GrantFiled: May 21, 2013Date of Patent: February 3, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
-
Publication number: 20150031859Abstract: This invention provides a crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structure model of said interferon useful for drug screening and/or drug design and the mimetic of said interferon. The invention further provides methods of designing and using new recombinant interferons with altered spatial configuration and three-dimensional structure.Type: ApplicationFiled: September 26, 2014Publication date: January 29, 2015Inventor: GUANGWEN WEI